VIM and metastatic neoplasm: We have shown that TRIM16 bound to and modulated vimentin expression in SCC cells, reduced cell motility and migration, and that the RFP-like domain was required for TRIM16's effects on SCC cell migration, suggesting that vimentin could be used as an anti-cancer therapeutic target in SCC patients with metastatic tumours.